Purpose of review: Older patients with diffuse large B-cell lymphoma (DLBCL) may face challenges in treatment due to comorbidities and tolerance of chemotherapy.
Recent findings: Older patients are at increased risk for treatment-related toxicity if they are unfit or frail by comprehensive geriatric assessment (CGA); however, treatment with non-anthracycline chemotherapy is associated with inferior outcomes in fit and unfit patients. Many older patients remain curable with standard R-CHOP chemotherapy. Careful assessment of frailty, function, and comorbidities using CGA may aid clinicians in initial therapy choices.
Keywords: Anthracycline; Comprehensive geriatric assessment; Diffuse large B-cell lymphoma; Elderly; Frail; Older.